Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[177Lu]Lu-DOTA-TATE with carboplatin, etoposide and atezolizumab in newly diagnosed extensive-stage small cell lung cancer
2024-513185-19-00Phase 2Authorised
- Sponsor
- Novartis
- Start
- Sep 2024
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 10
01
Overview
Phase 2, randomised trial of lutetium Lu 177 dotatate in small cell lung cancer (SCLC) (3 arms), sponsored by Novartis. Primary endpoints: Dose-limiting toxicities (DLTs) in Phase Ib, Adverse events (AEs) in Phase Ib and 3 more. Planned start Sep 2024; status: authorised.
02
Drugs
lutetium Lu 177 dotatate
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2024-513185-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513185-19-00.